Compare CSX Corporation (CSX) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs McKesson Corporation — how do they compare? CSX Corporation trades at $47.37 (market cap $86.70B), while McKesson Corporation trades at $921.5 (market cap $106.14B). The key difference: McKesson Corporation is the larger of the two by market cap, and CSX Corporation pays the higher dividend (1.2%). Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and McKesson Corporation for 74 Days on average.
| CSX | MCK | |
|---|---|---|
Market Cap | $86.70B | $106.14B |
Volume | 6,811,485 | 794,405 |
Sector | Industrials | Health |
52-Week High | $53.21 | $995.69 |
52-Week Low | $33.68 | $725.17 |
Typical Hold Time | 55 Days | 74 Days |
Enterprise Value | $104.66B | $112.67B |
Dividend Yield | 1.2% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.34, down 0.34% today, with a bearish technical signal from moving averages. Recent earnings show mixed quarterly results, beating in Q1 and Q2 2026 but missing in Q4 2025. Revenue has declined from $14.9B in 2022 to $14.1B in 2025, though net income margin remains strong at 22.21%. Analyst consensus is bullish with a $51.00 price target, supported by institutional buying and positive news on dividend sustainability.
The outlook for CSX hinges on reversing revenue declines and executing on projected 2026 growth. Risks include competitive pressures and economic sensitivity, but strong profitability and analyst support offer upside. Investors should weigh valuation premiums against operational resilience in the freight sector.
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
